Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102024 · ClinicalTrials.gov registry record · Phase 1
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00102024 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 30 participants.
The verdict
NCT00102024, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.
Interventions
- DRUG Unconjugated IDEC-159
- DRUG 111In-IDEC-159
- DRUG 90Y-IDEC-159
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102024
The ClinicalTrials.gov registry entry for NCT00102024 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Unconjugated IDEC-159 is the first listed.
NCT00102024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102024 about?
NCT00102024 is a clinical study titled "Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma". This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated do...
What is the current status of trial NCT00102024?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00102024?
The interventions under investigation include: Unconjugated IDEC-159 (DRUG), 111In-IDEC-159 (DRUG), 90Y-IDEC-159 (DRUG).
Who is sponsoring clinical trial NCT00102024?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.